Introduction {#s1}
============

Morphine, the most effective opioid analgesic, is clinically used for severe acute and chronic pain. An increasing number of studies have clarified that morphine could display beneficial protection. Morphine at low concentrations promoted cell proliferation and suppressed nicotine-induced cytotoxicity and cell death in PC12 cells ([@B3]). Low-dose morphine played a neuroprotective role in cellular and animal models of Parkinson\'s disease through inhibiting oxidative stress and endoplasmic reticulum stress, promoting autophagy activation, and improving mitochondrial function ([@B56]). Acute administration with morphine alleviated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced tremor symptoms in monkeys ([@B57]). In addition, morphine protected PC12 cells against the cytotoxicity of 1-methyl-4-phenylpyridinium through activating phosphatidylinositol 3-kinase (PI3K)/Akt pathway ([@B17]). Some groups demonstrated that preconditioning with morphine alleviated cerebral ischemia injury through activating the mTOR pathway ([@B5]) or mitochondrial KATP channels ([@B4]). However, repeated use of morphine will lead to various side-effects, such as antinociceptive tolerance, dependence, and addiction.

Morphine Addiction {#s2}
==================

Long-term treatment with morphine for the management of chronic pain will result in tolerance to the analgesic effect of morphine. In order to overcome tolerance, a higher dose of morphine is often required for the maintenance of analgesia, which will result in the development of severe side-effects, including respiratory depression, withdrawal symptoms, and rewarding effects with a high risk of relapse ([@B15]). Morphine addiction has become a major public health issue. An increasing number of studies have revealed that several brain regions, such as the ventral tegmental area (VTA), nucleus accumbens (NAc), and hippocampus (Hipp), are involved in morphine addiction ([@B29]). Although mechanisms underlying morphine-mediated processes remain the subject of much debate, morphine stimulation activates G protein-coupled opioid receptors and then induces significant molecular changes inside the cell, such as an inhibition of adenylate cyclase activity, and activation of potassium channels ([@B46]; [@B58]). In addition, other signalling pathways, including mitogen-activated kinases (MAPK), β-arrestin, phospholipase C, protein kinase, PI3K, and extracellular signal-regulated kinase (ERK) pathways, are also involved in morphine activity ([@B7]; [@B62]; [@B11]; [@B50]; [@B12]; [@B13]; [@B33]). Recently, the role of oxidative stress in morphine action has been paid more attention.

Oxidative Stress in Morphine Addiction {#s2_1}
--------------------------------------

A growing body of evidence has indicated that oxidative stress is involved in the development of addiction with several addictive drugs, including cocaine, methamphetamine, and morphine ([@B30]; [@B10]; [@B25]). Morphine could activate opioid receptors, and its treatment not only promoted the generation of free radicals, including reactive oxygen (ROS) or reactive nitrogen (RNS) species, but also decreased the activities of antioxidants in target cells ([@B51]). Morphine could induce ROS generation in a time- and concentration-dependent manner in SH-SY5Y cells and excessive ROS subsequently affected morphine addiction through involving µ-opioid receptors ([@B37]). Systemic morphine use also led to oxidative stress in animals. Oxidative stress levels were increased in the prefrontal cortex and Hipp of morphine-dependent rats ([@B16]). Abdel-Zaher and coworkers reported that glutamate levels and lipid peroxide malondialdehyde (MDA) levels were progressively increased in the brain of morphine-treated mice ([@B2]). What\'s more, brain intracellular reduced glutathione (GSH) levels and glutathione peroxidase (GSH-Px) activity were decreased in mice ([@B1]). In rats, subcutaneous injection of morphine also significantly increased lipid peroxidation, and decreased the activities of SOD and GSH-Px ([@B39]). GSH levels were depleted in cerebrospinal fluid sampled from cancer patients administrated with morphine intracerebroventricularly, which might render the central nervous system vulnerable to damage from oxidative stress ([@B19]). Morphine could alter intracellular levels of GSH-based cellular redox status, subsequently affect S-adenosylmethionine levels ([@B53]), and finally induce global DNA methylation changes ([@B54]).

In addition, morphine also affected other oxidative stress-related proteins. Long-term treatment with morphine not only increased the MDA level, but also decreased activities of SOD, glutathione-s-transfrase (GST), and catalase (CAT) in the liver of rats ([@B49]). Morphine accelerated the disease progression of HIV-infection in macaques due to the deteriorated oxidative stress, including the 50% drop of CAT and SOD ([@B44]). In rat primary neuronal striatal cells, three oxidative stress-related proteins - glyceraldehyde-3-phosphate dehydrogenase (GAPDH), dihydrolipoyl dehydrogenase (DLDH), and aldehyde dehydrogenase (ALDH) - were significantly upregulated after morphine administration ([@B8]). Proteomic analysis demonstrated that oxidative stress-related proteins, such as peroxiredoxin-2 and Heat shock protein 70 (Hsp70), were significantly decreased in the NAc of morphine-dependent monkeys ([@B9]) ([**Table 1**](#T1){ref-type="table"}).

###### 

Morphine-induced oxidative stress in cells, rodents, non-human primates and human.

  Species                               Morphine treatment                                                                                                   Effects                                                References
  ------------------------------------- -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ----------------
  human SH-SY5Y cells                   50 μM for 24 hour                                                                                                    ↑ROS generation                                        ([@B37])
  Rat primary neuronal striatal cells   10 μM for 5 days                                                                                                     ↑GAPDH, DLDH and ALDH                                  ([@B8])
  Rats                                  5 mg/kg for 14 days (i.p.)                                                                                           ↑MDA, ↓GSH                                             ([@B16])
  Rats                                  4 mg/kg for 1^st^ 10 days, 8 mg/kg 2^nd^ 10 days and 12 mg/kg for 3^rd^ 10 days (i.p.)                               ↑liver MDA and nitric oxide, ↓liver SOD, GST and CAT   ([@B49])
  Rats                                  45 mg/kg for 4 weeks (s.c.)                                                                                          ↑lipid peroxidation, ↓SOD and GSH-Px                   ([@B39])
  Mice                                  5 mg/kg twice daily for 7 days (s.c.)                                                                                ↑MDA and nitric oxide, ↓GSH and GSH-Px                 ([@B1]; [@B2])
  Rhesus monkeys                        3 mg/kg (day 1--7), 6 mg/kg (day 8--14), 9 mg/kg (day 15--21), 12 mg/kg (day 22--28), 15 mg/kg (day 29--90) (s.c.)   ↓peroxiredoxin-2 and Hsp70                             ([@B9])
  Macaques                              5 mg/kg (TID) for 20 weeks (i.m.)                                                                                    ↑MDA, ↓CAT and SOD                                     ([@B44])
  Cancer patients                       0.3 mg (icv.)                                                                                                        ↓cerebrospinal fluid GSH                               ([@B19])

i.p., intraperitoneally; s.c., subcutaneously; i.m., intramuscularly; icv., intracerebroventricularly.

Maintaining Redox Balance Inhibits Morphine Action {#s2_2}
--------------------------------------------------

Given the redox alteration in morphine action, antioxidants may provide a protective role in morphine addiction. SOD is an important intracellular antioxidant. Repeated doses of morphine in mice significantly decreased the activity of the mitochondrial isoform of MnSOD in the dorsal horn of the spinal cord due to the nitration of MnSOD by morphine ([@B41]). SOD-mimetic-agent-injection attenuated the effects of morphine on mitochondrial SOD activity ([@B40]). MnSOD overexpressed by recombinant herpes simplex virus in the periaqueductal gray of morphine-withdrawn rats suppressed the upregulated mitochondrial superoxide and the activation of endoplasmic reticulum stress ([@B24]).

Numerous studies have demonstrated that exogenous agents providing antioxidant activity could also inhibit the action of morphine. The accepted antioxidant, N-acetyl-cysteine, reversed the down-regulation of antioxidant genes (CAT and CuSOD) in SH-SY5Y cells treated with morphine ([@B47]). The antidepressant Venlafaxine prevented morphine antinociceptive tolerance at least partly because of its antioxidative properties, including the down-regulation of MDA and inhibition of total thiol and GSH-Px levels in the brains of mice ([@B38]). Fluoxetine, another prescribed antidepressant, also seemed a promising adjuvant to opioid analgesics due to its inhibition of morphine-induced changes in prooxidant-antioxidant balance ([@B21]). Atorvastatin, a lipid-lowering medication, could exhibit protective effects against both tolerance to antinociceptive effects of morphine and withdrawal-induced behaviors *via* normalizing the increased MDA in withdrawn mice ([@B43]). The polyphenol curcumin, the most abundant component of traditional Chinese medicine *Curcuma longa*, has antioxidant, anti-apoptotic, anti-inflammatory, immunomodulatory, anticancer, and neuroprotective properties. Curcumin lowered the increased lipid peroxidation and mitochondrial GSSG (oxidized GSH) levels in morphine-treated rats ([@B39]) and attenuated morphine tolerance and dependence by inhibiting the activity of Ca^2+^/calmodulin-dependent protein kinase II α ([@B23]). These studies suggest that the blocking effects of antioxidants to the action of morphine may provide a promising therapeutic strategy.

Thioredoxin {#s3}
===========

The thioredoxin (Trx) system, comprising Trx, thioredoxin reductase (TrxR), and coenzyme NADPH, plays a critical role in maintaining the cellular environment in a reduced state in both prokaryotes and eukaryotes ([@B22]). Human Trx is a 12 kDa multifunctional protein with a conserved redox catalytic site (-Cys-Gly-Pro-Cys-) ([@B6]). The mutual transformation of dithiol and disulfide means Trx plays a vital role in regulating cellular redox balance ([@B28]). Trx-1, a major isoform located to cytoplasm, can directly scavenge ROS induced by a wide variety of stressors, such as UV irradiation and viral infections. Trx-1 can also inhibit cellular apoptosis ([@B60]) because it acts as an endogenous negative regulator of apoptosis signal-regulating kinase 1 (ASK1) in the cytoplasm and inhibits ASK1-dependent apoptotic pathway ([@B48]). It has been reported that Trx-1 expression is enhanced in both chronic and acute stress models and attenuate epinephrine stress-induced DNA damage *via* the negative regulation of β-arrestin-1 ([@B26]; [@B27]). Our previous studies have demonstrated that Trx-1 shows a neuroprotective role in central nervous system diseases, including Parkinson\'s disease and cerebral ischemia ([@B59]; [@B61]). Interestingly, Trx-1 is involved in the addiction of drugs, including morphine ([@B36]; [@B20]).

The Increased Expression and the Role of Trx-1 Upon Morphine Administration {#s3_1}
---------------------------------------------------------------------------

So far, only a few studies have reported that Trx-1 expression is increased upon morphine administration. Trx-1 was induced through opioid receptors and the activation of PI3K and ERK pathways in morphine-treated SH-SY5Y cells ([@B34]). Morphine exposure increased the expression of Trx-1 in dentate gyrus (DG, a brain region involved in memory consolidation), which was reversed by the pretreatment of a corticotropin-releasing factor 1 receptor (CRF1R) antagonist, CP-154,526, with no changes in the paraventricular nucleus (PVN) ([@B18]). García-Carmona and coworkers found that phosphorylated cAMP-responsive element-binding protein (p-CREB) positive neurons in DG also expressed Trx-1 ([@B18]), suggesting that Trx-1 could activate CREB and increase the rewarding effects of morphine ([**Table 2**](#T2){ref-type="table"}). The results are consistent with another study in which Trx-1 ameliorated the learning and memory deficits in a mouse model of Parkinson\'s disease *via* the restoration of p-CREB in the Hipp ([@B63]).

###### 

The effects and molecular mechanisms of Trx-1 and GGA on morphine addiction.

  Brain areas           Effects                                                                   Mechanisms                                                                                      References
  --------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------
  DG                    Morphine-induced increase of Trx-1 enhanced the rewarding effects         Activating CREB                                                                                 ([@B18])
  VTA and NAc           Overexpression of Trx-1 inhibited morphine-induced CPP                    Upregulating the endogenous concentration of GABA and the expression of GABA~B~ receptor        ([@B32])
  NAc                   Inhibiting CPP and attenuating the naloxone-induced withdrawal syndrome   Suppressing the activation of CREB, and the expression of ∆FosB and cyclin-dependent kinase 5   ([@B35])
  NAc and hippocampus   Inhibiting morphine reinstatement-induced CPP                             Attenuating the activation of NR2B/p-CaMKII/p-ERK/p-CREB pathway                                ([@B20])

Morphine also markedly increased the expression of Trx-1 in the nucleus accumbens (NAc) of C57BL/6 mice ([@B35]). Interestingly, the Trx-1 expression showed a notable elevation in the liver and kidney of morphine-treated mice ([@B36]). Trx-1 expression was induced by morphine in the ventral tegmental area (VTA) and NAc of mice ([@B32]), two brain regions involved in morphine-induced conditioned place preference (CPP) for both opiates and psychostimulants ([@B14]; [@B64]). Li et al. further clarified that Trx-1 overexpression in transgenic mice inhibited morphine-induced CPP through upregulating the endogenous concentration of γ-aminobutyric acid (GABA) and the expression of GABA~B~ receptor in the VTA and NAc ([@B32]) ([**Table 2**](#T2){ref-type="table"}). Considering the critical role of Trx-1 in maintaining the cellular redox state, the increase of Trx-1 expression in morphine-induced CPP might be a compensatory mechanism of stress systems for the maintenance of neuroprotection.

The Effects of Geranylgeranylacetone on Morphine Treatment {#s3_2}
----------------------------------------------------------

Geranylgeranylacetone (GGA) is a clinical drug, extensively used for ulcer therapy ([@B42]). Now GGA has become an accepted pharmacological inducer of Trx-1 ([@B52]). Luo et al. demonstrated that pre-treatment with GGA significantly reduced morphine-induced locomotion, inhibited the CPP, and attenuated the naloxone-induced withdrawal syndromes, such as jumping, forepaw tremor, and rearing, through suppressing the activation of CREB, and inhibiting the expressions of ∆FosB and cyclin-dependent kinase 5 in the NAc of C57BL/6 mice ([@B35]). Interestingly, the effect of increased Trx-1 by GGA on the activation of CREB in the NAc is contrary to that by CP-154,526 in DG ([@B18]). In addition, GGA also inhibited reinstatement of morphine-induced CPP through strengthening the expression of Trx-1 and regulating the N-methyl d-aspartate receptor 2B subunit (NR2B)/ERK pathway in the NAc and Hipp, a brain region participating in associative processes such as declarative memory ([@B20]) ([**Table 2**](#T2){ref-type="table"}), suggesting that GGA may be a promising therapeutic drug for morphine-induced relapse. These studies suggest that enhancement of Trx-1 expression in the brain by using noncytotoxic pharmacological inducers may provide a novel therapeutic strategy for morphine dependence.

Conclusion and Expectation {#s4}
==========================

In summary, chronic morphine treatment has been shown to lead to oxidative stress, which plays an important role in the development of morphine tolerance and dependence. An increasing number of studies have clarified that maintaining redox balance through restoration of endogenous antioxidant proteins or treatment with antioxidant agents inhibits the action of morphine. As an antioxidant protein, Trx-1 could effectively inhibit the effects of morphine administration. In this article we reviewed that overexpression of Trx-1 or enhancement of Trx-1 expression by GGA, the noncytotoxic pharmacological inducer of Trx-1, inhibited morphine-induced CPP. At this stage, the studies are extremely few and limited to focusing on the effects of Trx-1 on morphine addiction mainly in rodent models. Their effects on morphine withdrawal and relapse should be investigated in future research. Besides that, nonhuman primate models of morphine addiction should be also developed to accelerate the clinical application of Trx-1 in the future. Trx-1 will provide a novel therapeutic strategy for morphine abuse.

Remarkably, GGA is also the pharmacological inducer of Hsp70, a soluble intracellular chaperone protein ([@B31]). Although GGA was reported to protect mice against morphine-induced hyperlocomotion, rewarding effect, and withdrawal syndromes, as well as morphine-induced hepatic and renal damage ([@B35]; [@B36]), GGA-induced Hsp70 expression in the core of NAc promoted the development of behavioral sensitization, an important behavioral characteristic of drug-addicted animals, providing a biological target for long-lasting adaptations with relevance to morphine addiction ([@B55]).Recent research has reported that pre-treatment with an Hsp70 transcriptional inducer GGA promoted the development of morphine analgesic tolerance ([@B45]), suggesting that GGA is not clinically beneficial to the analgesic effect of morphine. Regarding these effects of GGA, further studies are needed to develop much more optimal pharmacological inducers of Trx-1.
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